Opinion|Videos|September 30, 2024
Overcoming Barriers to Prescribing First-Line Medications for CRM Conditions
Key Takeaways
- Enhancing physician awareness and understanding of SGLT2 inhibitors and GLP1-receptor agonists can increase prescription rates.
- Streamlining insurance approval processes and advocating for policy changes are crucial for improving medication coverage.
The expert panel analyzes strategies for overcoming barriers to prescribing first-line medications for cardiometabolic conditions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Despite being approved for first-line treatment, medications such as SGLT2 inhibitors and GLP1-receptor agonists are not frequently prescribed to qualified patients. What has been effective in your practice to get these first line medications covered in the patient population who needs it the most?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Combined Eosinophil, CT Measures Predict Smell Recovery After CRSwNP Surgery
2
Stereotactic Body Radiation Therapy Equally Effective as Surgery in Stage I NSCLC
3
Boosting RSV Vaccination in Older Adults Could Save Thousands
4
New PBM Laws Seek to Protect Independent Pharmacies but Could Raise Costs, Limit Patient Access
5
